ECPC works for a Europe of equality, where all European cancer patients have timely and aﬀordable access to the best treatment and care available, throughout their life. ECPC believes that cancer patients are the most important partners in the ﬁght against cancer and against all the cancer-related issues aﬀecting our society. Policy makers, researchers, doctors and industry should recognise cancer patients as co-creators of their own health.
Every year, the European Cancer Patient Coalition (ECPC) produces its Annual Action Plan , in which it defines key activities to be performed during the following year. The Action Plan, produced by the ECPC Secretariat under the guidance of the ECPC Board, is the implementation blueprint of ECPC Strategy , these can be divided into the following two main categories:
ECPC believes in the value of multidisciplinarity, and recognises the need for informed scientifically correct policy action. Our policy initiatives enjoy the scientific expertise gained through participation in several key EU funded projects and built on mutual collaboration of Institutional Partners and active Members.
ECPC is one of the few cancer patient organisation actively involved in the design and implementation EU funded Health and Research projects, among other ongoing activities. The European Cancer Patient Coalition participates in the EU 3rd Health Progrmme, as well as, several European Union's Research and Innovation framework programmes: this includes the Seventh Framework Programme (FP7), IMI 1 and IMI 2 intitatives under the current Horizon 2020 (H2020). ECPC emphasises the importance of involving patients as co-researchers and strongly advocates for the best partnership model between both researchers and patients, allowing patients to contribute their unique experience working towards a more patient-centric study while participating in crucial project decisions.
ECPC is an active member in the Worldwide Innovative Networking (WIN) Consortium in personlized cancer medicine,contributing to the mission of rapidly translating personlized cancer medicine discoveries into standards of patient care worldwide.